HS-10370 + adebrelimab

HS-10370 + adebrelimab is a combination of two investigational/approved drugs under evaluation for the treatment of patients with advanced solid tumors, primarily non-small cell lung cancer (NSCLC) and other KRAS G12C-mutated cancers. **HS-10370** is an orally bioavailable, highly selective, covalent small molecule inhibitor targeting the KRAS G12C mutation, which is found in a subset of NSCLC and other solid tumors. It irreversibly binds to the mutant KRAS G12C protein, thereby inhibiting downstream oncogenic signaling. **Adebrelimab** is a fully humanized IgG4 monoclonal antibody targeting programmed cell death-ligand 1 (PD-L1). It selectively blocks the interaction of PD-L1 with PD-1 and B7-1 to reactivate anti-tumor T-cell immune responses, acting as an immune checkpoint inhibitor. The combination aims to enhance anti-tumor efficacy by combining direct oncogenic pathway inhibition (HS-10370) with immune checkpoint blockade (adebrelimab). Clinical studies are ongoing to assess the safety and efficacy of this combination in solid tumors, especially those harboring KRAS G12C mutations[1][2][3][4][6][7][9][10].